特纳综合征中的生长激素治疗与左心室维度
Growth hormone treatment and left ventricular dimensions in Turner syndrome.
作者信息
Matura Lea Ann, Sachdev Vandana, Bakalov Vladimir K, Rosing Douglas R, Bondy Carolyn A
机构信息
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
J Pediatr. 2007 Jun;150(6):587-91. doi: 10.1016/j.jpeds.2007.02.009.
OBJECTIVE
To determine whether cardiac dimensions were different in girls with Turner syndrome (TS) who received growth hormone (GH) compared with those who did not receive GH.
STUDY DESIGN
This retrospective, cross-sectional study analyzed echocardiograms in 86 females with TS divided into GH-treated (n = 67) and untreated (n = 19) groups. The subjects all participated in the National Institutes of Health protocol between 2001 and 2006.
RESULTS
The average age was 16.2 years (range, 10 to 25 years), and average duration of GH treatment was 4.4 years (range, 1 to 14 years). The GH-treated group was taller by approximately 7 cm (P = .004), but cardiac dimensions normalized to body surface area (BSA), including septal and posterior wall thickness and left ventricular (LV) mass and internal diameters, did not differ significantly between the 2 groups. The fractional shortening index was similar in the 2 groups. Multiple regression analyses indicated that BSA, but not duration of GH treatment, predicted LV dimensions in girls with TS.
CONCLUSIONS
GH treatment of girls with TS increases stature but does not disproportionately affect cardiac dimensions.
目的
确定接受生长激素（GH）治疗的特纳综合征（TS）女孩与未接受GH治疗的女孩相比，心脏大小是否存在差异。
研究设计
这项回顾性横断面研究分析了86例TS女性的超声心动图，这些女性被分为GH治疗组（n = 67）和未治疗组（n = 19）。所有受试者均在2001年至2006年期间参与了美国国立卫生研究院的方案。
结果
平均年龄为16.2岁（范围为10至25岁），GH治疗的平均持续时间为4.4年（范围为1至14年）。GH治疗组身高约高7厘米（P = .004），但按体表面积（BSA）标准化的心脏大小，包括室间隔和后壁厚度、左心室（LV）质量和内径，两组之间无显著差异。两组的缩短分数指数相似。多元回归分析表明，在TS女孩中，预测LV大小的是BSA，而非GH治疗持续时间。
结论
对TS女孩进行GH治疗可增加身高，但不会对心脏大小产生不成比例的影响。
Zotero 插件